For GSK, Lots Of Drugs In R&D, But Many Are Long-Term
Management highlighted pipeline drugs in respiratory disease, HIV, immuno-oncology and vaccines, but a lot of the drugs in development are early- to mid-stage where the success rate remains uncertain. The meeting isn’t likely to change investor sentiment in the near-term.
You may also be interested in...
The company initiated a Phase III development program for the oral HIF-PH inhibitor daprodustat as a treatment for anemia associated with chronic kidney disease. Two trials will enroll 7,500 patients.
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.